- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03861455
Efficacy and Safety of Dupilumab Chronic Hands Eczema Refractory to Highly Potent Topical Corticosteroids (DUPECZEMAIN)
DUPECZEMAIN : Double Blind Placebo-controlled Randomized Multicenter Study Assessing the Efficacy and Safety of Dupilumab in Moderate to Severe Chronic Hands Eczema Refractory to Highly Potent Topical Corticosteroids
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Study Type
Enrollment (Estimated)
Phase
- Phase 2
Contacts and Locations
Study Contact
- Name: Marie TAUBER, MD
- Phone Number: 33 618569203
- Email: tauber.ma@chu-toulouse.fr
Study Locations
-
-
-
Bordeaux, France, 30000
- Recruiting
- Saint André Hospital
-
Principal Investigator:
- Julien Seneschal, MD
-
Contact:
- Julien Seneschal, MD
-
Montpellier, France, 34000
- Recruiting
- Hopital Saint Eloi
-
Contact:
- Aurelie Du Thann, MD
-
Principal Investigator:
- Aurelie Du Thann, MD
-
Toulouse, France, 31059
- Recruiting
- Larrey Hospital
-
Contact:
- Marie TAUBER, MD
-
Principal Investigator:
- Marie TAUBER, MD
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Patients affiliated to a social insurance protection regimen.
- Patients with moderate to severe chronic (>6 months) hand eczema with an Investigator global assessment (IGA) of 3 or 4 (out of a scale of 0 to 4).
- Patients intolerant (according to the physician) or resistant to highly potent topical corticosteroids. Inadequate response (resistance) to highly potent topical corticosteroids is defined as a history of failure to achieve and maintain remission or a low disease activity state (comparable to an IGA score of 0 [indicating clear] to 2 [indicating mild]) despite treatment with a daily regimen of highly potent topical corticosteroids applied for 14 days or for the maximum duration recommended for highly potent topical corticosteroids.
- Patients who are able to understand the study procedures including the ability to complete patient-oriented questionnaires.
- Patients who are able to apply a stable dose of emollients within 7 days before the baseline visit.
- Patients who agree to sign the written informed consent.
Exclusion Criteria:
- Hypersensitivity to dupilumab or to any of its ingredients
- Patients under adult autonomy protection system
- Any other condition (e;g., psoriasis) on the hands that according to the investigator will impair the ability to evaluate treatment effect.
- Treatment with topical corticosteroids or topical calcineurin inhibitors within one week of baseline.
- Treatment with oral immunosuppressants (including cyclosporine, methotrexate, azathioprine, mycophenolate mofetil), alitretinoin or phototherapy within 4 weeks of baseline visit.
- Treatment with an investigational drug within 8 weeks (or 5 half-lives) of baseline.
- Active chronic infection requiring the use of a systemic antibiotic within 2 weeks before study start.
- Known or suspected history of immunosuppression, including history of invasive opportunistic infections (e.g., tuberculosis, histoplasmosis, listeriosis, coccidioidomycosis, pneumocystis, aspergillosis) despite infection resolution; or unusually frequent, recurrent, or prolonged infections, per investigator judgment.
- History of human immunodeficiency virus (HIV) infection or positive HIV serology at screening.
- Positive for hepatitis B surface antigen, hepatitis B core antibody, or hepatitis C antibody at the screening visit.
- Patients with known helminth infections.
- Pregnant or breastfeeding women, or women planning to become pregnant or breastfeed during the study. Women of childbearing potential who are sexually active and unwilling to use an adequate birth control method
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Double
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: dupilumab group
patient receive dupilumab 300 mg every 2 weeks after a 600 mg-loading dose of dupilumab on day 0
|
patient receive dupilumab 300 mg every 2 weeks after a 600 mg-loading dose of dupilumab on day 0
|
Placebo Comparator: placebo group
patient receive placebo
|
patient receive placebo
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
severity score mTLSS (modified Total Lesion Symptom Score)
Time Frame: Week 16
|
The primary outcome measure will be the 16-week percent change since baseline of the severity score mTLSS (modified Total Lesion Symptom Score) The mTLSS combines an evaluation of hand eczema lesions severity including 6 key signs (erythema, desquamation, lichenification/hyperkeratosis, vesiculae, oedema, fissures) and the intensity of pruritus and pain. The seven individual CHE symptoms; (erythema, scaling, lichenification or hyperkeratosis, vesiculation, edema, fissures, and pruritus/pain) form the composite scale of mTLSS' strength and each one of them scores from 0 (mild) to 3 (severe). The scores are summed, extending from a base estimation of 0 (no signs or symptoms) to the most extreme of 21 (more serious disease). |
Week 16
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Evolution of pruritus
Time Frame: Week 16
|
Evolution of pruritus associated with Chronic Hands Eczema at week 16 since baseline measured with a visual analog scale (VAE) from 0 (no itching) to 100 (intense itching).
|
Week 16
|
Evolution of pain
Time Frame: Week 16
|
Evolution of pain associated with Chronic Hands Eczema at week 16 since baseline measured with a visual analog scale from 0 (no pain) to 100 (intense skin pain).
|
Week 16
|
Improvement of quality of life
Time Frame: Week 16
|
Improvement of quality of life at week 16 since baseline measured by DLQI (Dermatology Life Quality Index) composed of 10 questions (4 possibilities per questions: very much, a lot, a little, not at all).
|
Week 16
|
Improvement of quality of life by EQ-5D-5L
Time Frame: Week 16
|
Improvement of quality of life at week 16 since baseline measured by EQ-5D-5L.
The EQ-5D-5L consists of 2 components: a descriptive system of the respondent's health and a rating of his or her current health state using a 0 to 100 mm VAS.
The descriptive system comprises the following 5 dimensions: mobility, self-care, usual activities, pain/discomfort, and anxiety/depression.
Each dimension has 5 levels: no problems, slight problems, moderate problems, severe problems, and extreme problems.
The respondent is asked to indicate his or her health state by ticking (or placing a cross) in the box associated with the most appropriate statement in each of the 5 dimensions.
The VAS records the respondent's self-rated health on a vertical VAS where the endpoints are labeled "best imaginable health state" and "worst imaginable health state."
This information can be used as a quantitative measure of health outcome.
|
Week 16
|
evolution of sleep loss
Time Frame: Week 16
|
Evolution of sleep loss associated with Chronic Hands Eczema at week 16 since baseline measured with a visual analog scale from 0 (no sleep disorder) to 100 (severe sleep loss).
|
Week 16
|
IGA - Clearance
Time Frame: Week 16
|
Clearance or almost clearance of hand eczema at week 16 as defined by an Investigator's global assessment (IGA) of 0 or 1, on a 5 range scale ( from 0 = Clear to 4 = severe disease)
|
Week 16
|
PaGa - Clearance
Time Frame: Week 16
|
Clearance or almost clearance of hand eczema at week 16 as assessed by the Patient's global assessment (PaGa) of 0 or 1.
The PGA is a single-item question asking the patient how they would rate their overall symptoms.
The 5 categories of responses range from "no symptoms"(0) to "severe."(4)
|
Week 16
|
Improvement of work productivity
Time Frame: Week 16
|
Improvement of work productivity at week 16 since baseline as assessed by the WPAI questionnaire (Work Productivity and Activity Impairment).
The WPAI consists of 6 items grouped into 4 domains: absenteeism (work time missed), presenteeism (impairment at work/reduced on-the-job effectiveness), work productivity loss (overall work impairment/absenteeism plus presenteeism), and activity impairment.
Scores are calculated as impairment percentages, with higher scores indicating greater impairment and less productivity.
|
Week 16
|
Evolution of the Eczema Area and Severity Index (EASI)
Time Frame: Week 16
|
Evolution of the Eczema Area and Severity Index at week 16 since baseline in patients who have eczema on other parts of the body than the hands.
The EASI score ranges are between 0 (no eczema) and 72.
Higher values represent a worse outcome.
|
Week 16
|
Incidence of Treatment-Emergent Adverse Event
Time Frame: Week 16
|
The safety throughout the course of the study (at 20 weeks since baseline) by monitoring adverse events, serious adverse events, injection site reactions
|
Week 16
|
evolution of laboratory parameters - full blood count
Time Frame: Week 16
|
The evolution of laboratory parameters (full blood count) at week 16 since baseline
|
Week 16
|
evolution of laboratory parameters - transaminases
Time Frame: Week 16
|
The evolution of laboratory parameters (transaminase) at week 16 since baseline
|
Week 16
|
evolution of laboratory parameters - total immunoglobulin E
Time Frame: Week 16
|
The evolution of laboratory parameters (total immunoglobulin E) at week 16 since baseline
|
Week 16
|
evolution of laboratory parameters - specific immunoglobulin E
Time Frame: Week 16
|
The evolution of laboratory parameters (specific immunoglobulin E) at week 16 since baseline
|
Week 16
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Marie Tauber, Toulouse University Hospital
Publications and helpful links
General Publications
- Blauvelt A, de Bruin-Weller M, Gooderham M, Cather JC, Weisman J, Pariser D, Simpson EL, Papp KA, Hong HC, Rubel D, Foley P, Prens E, Griffiths CEM, Etoh T, Pinto PH, Pujol RM, Szepietowski JC, Ettler K, Kemeny L, Zhu X, Akinlade B, Hultsch T, Mastey V, Gadkari A, Eckert L, Amin N, Graham NMH, Pirozzi G, Stahl N, Yancopoulos GD, Shumel B. Long-term management of moderate-to-severe atopic dermatitis with dupilumab and concomitant topical corticosteroids (LIBERTY AD CHRONOS): a 1-year, randomised, double-blinded, placebo-controlled, phase 3 trial. Lancet. 2017 Jun 10;389(10086):2287-2303. doi: 10.1016/S0140-6736(17)31191-1. Epub 2017 May 4.
- Halioua B. [Hand eczema : disability and impact]. Ann Dermatol Venereol. 2014 Jun;141 Suppl 1:S111-6. doi: 10.1016/S0151-9638(14)70148-6. French.
- Cortesi PA, Scalone L, Belisari A, Bonamonte D, Cannavo SP, Cristaudo A, De Pita O, Gallo R, Giannetti A, Gola M, Pigatto PD, Mantovani LG. Cost and quality of life in patients with severe chronic hand eczema refractory to standard therapy with topical potent corticosteroids. Contact Dermatitis. 2014 Mar;70(3):158-68. doi: 10.1111/cod.12130. Epub 2013 Sep 19.
- Fowler JF, Graff O, Hamedani AG. A phase 3, randomized, double-blind, placebo-controlled study evaluating the efficacy and safety of alitretinoin (BAL4079) in the treatment of severe chronic hand eczema refractory to potent topical corticosteroid therapy. J Drugs Dermatol. 2014 Oct;13(10):1198-204.
- Molin S, Merl J, Dietrich KA, Regauer M, Flaig M, Letule V, Saucke T, Herzinger T, Ruzicka T, Hauck SM. The hand eczema proteome: imbalance of epidermal barrier proteins. Br J Dermatol. 2015 Apr;172(4):994-1001. doi: 10.1111/bjd.13418. Epub 2015 Feb 26.
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- RC31/18/0269
- 2018-002830-19 (EudraCT Number)
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Chronic Hand Eczema
-
University Hospital, Gentofte, CopenhagenTrygFonden, DenmarkCompletedChronic Hand Dermatitis | Chronic Hand EczemaDenmark
-
LEO PharmaRecruiting
-
LEO PharmaCompletedChronic Hand EczemaFrance, Germany, Italy, Poland, Spain, United Kingdom, Austria, Canada, Norway, Slovakia
-
LEO PharmaRecruitingChronic Hand EczemaSpain, France, Belgium, Australia, Canada, Poland, United Kingdom
-
LEO PharmaCompletedChronic Hand EczemaGermany
-
LEO PharmaCompletedChronic Hand EczemaUnited States, Germany, Denmark
-
Jacob Pontoppidan ThyssenThe Novo Nordic FoundationRecruiting
-
Arcutis Biotherapeutics, Inc.CompletedChronic Hand EczemaUnited States, Australia, Canada
-
Pierre Fabre MedicamentClinSearchWithdrawn
-
LEO PharmaCompletedChronic Hand EczemaPoland, Belgium, Canada, Denmark, Germany, Netherlands, Spain, France, Italy, United Kingdom
Clinical Trials on Dupilumab
-
Brigham and Women's HospitalRegeneron PharmaceuticalsRecruiting
-
Akron Children's HospitalRegeneron Pharmaceuticals; Ohio State UniversityNot yet recruiting
-
University of MichiganRegeneron PharmaceuticalsRecruiting
-
Northwestern UniversityRecruitingSkin DiseasesUnited States
-
University of California, San FranciscoRecruiting
-
Fundació Institut de Recerca de l'Hospital de la...RecruitingAsthma; EosinophilicSpain
-
Montefiore Medical CenterRegeneron PharmaceuticalsRecruitingChronic Rhinosinusitis With Nasal PolypsUnited States
-
Johns Hopkins UniversityDoris Duke Charitable FoundationRecruiting
-
University of RochesterNot yet recruiting